Investigational Drug for Locally Advanced or Metastatic Solid Tumors

Trial ID:
IRB-15-6698
Darren Sigal, M.D.
This is an open-label, phase 2 study evaluating Entrectinib for the treatment of patients with locally advanced or metastatic solid tumors that harbor NTRK1/2/3, ROS1, or ALK gene rearrangements.

Inclusion Criteria

  • Male or female, 18 years of age or older
  • Pathology confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement. Tumor testing will be provided through the study.

Exclusion Criteria

  • Current participation on another clinical trial
  • Active gastrointestinal disease or other malabsorption syndromes that would reasonably impact drug absorption

Contact Info: